Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.
What this study shows
Beyond rapamycin, the same ITP program found acarbose extended male median lifespan by 22% - evidence that the registry surfaces real positive hits too, not only negative results.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Mouse (genetically heterogeneous, ITP, 3 sites)); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Mouse (genetically heterogeneous, ITP, 3 sites) |
| Journal | Aging Cell |
| Year | 2014 |
| Peer reviewed | Yes |
| Record last updated | 2026-07-29 |
| Source | DOI 10.1111/acel.12170 · PMID 24245565 · Free full text (PMC3954939) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Acarbose, 17-α-estradiol, NDGA, methylene blue (dietary/pharmacologic) |
| Target | Metabolic/aging pathways |
| Model | Mouse (genetically heterogeneous, NIA ITP, 3 sites) |
| Effect | Acarbose extended male median lifespan by 22% (female 5%); EST and NDGA extended lifespan preferentially in males |
| Dose | Acarbose at 1000 mg kg −1 diet (1000 ppm) from 4 months of age |
| Sample size | not stated |
| Effect size | Male median lifespan increased by 22% (P < 0.0001); female median lifespan increased by 5% (P = 0.01) (pooled data). |
| Limitations | not stated |
In the Atlas
Related topics
Open questions that cite this study
- Cited as supporting evidence for the open question Does the larger rapamycin benefit in female mice survive equal drug exposure, and is it set by hormones or by chromosomes?.
- Cited as supporting evidence for the open question Rapamycin + AMPK-axis drugs (acarbose / metformin): a male-mouse survival signal from cross-cohort comparison, untested in humans.
More studies on this topic
- Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice (2022)
- Disruption of the insulin/IGF-1 signaling pathway in Caenorhabditis elegans dramatically increases male longevity and enhances reproductive health late in life (2026)
- Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice (2011)
- Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice (2016)
Was this page useful?
Thank you. Your answer was counted anonymously.